While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The In
Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.
Medtronic stock snapshot after recent trading performance Medtronic (MDT) has drawn investor attention after a mixed stretch in its share price, with the stock roughly flat over the past day, up in th
Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.
MDT is betting on ablation, robotics and hypertension therapies as next growth drivers, but tariffs, FX and pricing pressures cloud near-term upside.
CEO Rainer Blair said Danaher has the money and “leadership bandwidth” to strike further deals across any of its three business areas.
ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects.
MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.
View interactive chart, options flow, and AI analysis for MDT on Zorveq Finance.
Open MDT Chart & Analysis →